Cargando…
KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
BACKGROUND: We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-κB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing NF-κB activity and upregulating cytokine secretion – e...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719595/ https://www.ncbi.nlm.nih.gov/pubmed/19619321 http://dx.doi.org/10.1186/1479-5876-7-63 |